Why is GLP-1 no longer covered by insurance?
Insurance companies and employers are dropping or restricting coverage for GLP-1 medications primarily due to unsustainable financial costs and surging patient demand for weight-loss indications like Wegovy and Zepbound.
Why Coverage is Being Dropped
- Soaring Financial Impact: Brand-name GLP-1 drugs often cost between $900 and $1,350 per month list price. With a massive portion of the U.S. adult population qualifying for obesity treatment, covering these drugs for weight loss threatens massive budget deficits for state plans and corporate health programs.
- Distinction Between Weight Loss and Diabetes: Most insurers and employers are specifically eliminating coverage for chronic weight management, while continuing to cover GLP-1s (like Ozemic and Mounjaro) when prescribed for Type 2 diabetes.
- Flawed Traditional Insurance Models: Traditional insurance is designed to pool risk for unexpected medical events (like a broken leg), not high-cost, lifestyle or chronic maintenance drugs demanded by millions of people simultaneously, which causes premiums to skyrocket.
- Stricter Utilization Management: Even when coverage isn't fully dropped, plans are adding stricter hurdlesβsuch as higher cost-sharing, mandatory prior authorizations, or dropping specific brand names in favor of cheaper alternatives.